Sapu BioScience

Sapu Bioscience is a US-based biotech founded in 2019, focusing on RNA and small molecule therapeutics for oncology and virology. Its core asset is OT-101, a first-in-class anti-TGF-β RNA therapeutic that has demonstrated single-agent activity in relapsed/refractory cancer patients and anti-viral effects against COVID-19. The company leverages deep drug development expertise, holds over 100 patent applications, and is pursuing rare pediatric cancer indications, including a designation for Diffuse Intrinsic Pontine Glioma (DIPG). Sapu is currently pre-revenue and advancing its key programs through clinical trials.

First-in-class RNA therapeutics platform targeting TGF-β for immuno-oncology and antiviral applications, complemented by small molecule drug discovery.

Sapu competes in the broad TGF-β inhibitor space, which includes companies developing antibodies, small molecules, and other modalities. Its specific RNA approach is a differentiator. In DIPG, it faces limited direct competition but must prove efficacy where most therapies fail. The COVID-19 antiviral space is crowded and rapidly evolving.